217 related articles for article (PubMed ID: 14730509)
1. Hypercalcemia of malignancy.
Body JJ
Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
[TBL] [Abstract][Full Text] [Related]
2. [How to treat tumor-induced hypercalcemia].
Body JJ
Rev Prat; 2003 Dec; 53(19):2128-35. PubMed ID: 15008469
[TBL] [Abstract][Full Text] [Related]
3. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tumor-induced hypercalcemia: a solved problem?
Body JJ; Mancini I
Expert Rev Anticancer Ther; 2003 Apr; 3(2):241-6. PubMed ID: 12722883
[TBL] [Abstract][Full Text] [Related]
5. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
6. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Lortholary A
Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
9. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
10. Bone metastases and tumor-induced hypercalcemia.
Body JJ
Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
[TBL] [Abstract][Full Text] [Related]
11. Modern management of malignant hypercalcemia.
Legrand SB
Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
14. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
[TBL] [Abstract][Full Text] [Related]
15. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
Heatley S
Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
[TBL] [Abstract][Full Text] [Related]
16. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
19. Safety and convenience of a 15-minute infusion of zoledronic acid.
Berenson J; Hirschberg R
Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
[TBL] [Abstract][Full Text] [Related]
20. Update on the medical treatment of hypercalcemia of malignancy.
Hall TG; Schaiff RA
Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]